# EDGAR Filing Document

**Accession Number:** 0002126478
**File Stem:** 0000310158-26-000109
**Filing Date:** 2026-5
**Character Count:** 11130
**Document Hash:** 65a2ef4805be446b578b3de7a4c06aa8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000310158-26-000109.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0000310158-26-000109

**CONFORMED SUBMISSION TYPE**: 3/A

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260501

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Maraldo David R.
- **CENTRAL INDEX KEY:** 0002126478

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-06571
- **FILM NUMBER:** 26941876

**MAIL ADDRESS:**
- **STREET 1:** 126 E. LINCOLN AVE.
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merck & Co., Inc.
- **CENTRAL INDEX KEY:** 0000310158
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 221918501
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 126 EAST LINCOLN AVENUE
- **STREET 2:** P.O. BOX 2000
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065
- **BUSINESS PHONE:** 908-740-4000

**MAIL ADDRESS:**
- **STREET 1:** 126 EAST LINCOLN AVENUE
- **STREET 2:** P.O. BOX 2000
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Merck & Co. Inc.
- **DATE OF NAME CHANGE:** 20091103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SCHERING PLOUGH CORP
- **DATE OF NAME CHANGE:** 19920703

## Ex-24

```

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Jennifer Zachary,
Jon Filderman, and Kelly Grez,signing singly, the undersigned's

true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer or director
of Merck & Co., Inc. (the "Company"), Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities
Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable
to complete and execute any such 3, 4 or 5, complete
and execute any amendment or amendments thereto, and timely
file such form with the United States Securities and
Exchange Commission and any stock exchange or similar
authority; and

(3) take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-in-fact, may be
of benefit to, in the best interest of, or legally required by,
the undersigned, it being understood that the documents executed
by such attorney-in-fact on behalf of the undersigned pursuant
to this Power of Attorney shall be
in such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform
any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any
of the rights and powers herein granted, as fully to all intents
and purposes as the undersigned might or
could do if personally present, with full power of substitution or
revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted.

The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities
to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4 and 5 with respect
to the undersigned's holdings of and transactions in securities issued
by the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
This Power of Attorney revokes all previous powers of attorney with
respect to the subject matter of this Power of Attorney.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 17th day of April, 2026.

/s/ David Maraldo
David Maraldo

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Maraldo David R.<br><sub>(Last) (First) (Middle)</sub><br>126 EAST LINCOLN AVENUE<br><sub>(Street)</sub><br>RAHWAY, NJ 07065<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP & Pres. MMD_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Merck & Co., Inc. [ MRK ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 17819.434 | D |  |
| Common Stock - 401(k) Plan |  |  |  |  |  |  |  | 8359.14 | I | By 401 (k) |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(2)</sup> |  |  |  |  |  |  | 2024-05-02<sup>(1)</sup> | 2026-05-02 | Common Stock | 552 |  |  | D |  |
| Restricted Stock Unit | <sup>(2)</sup> |  |  |  |  |  |  | 2025-04-30<sup>(3)</sup> | 2027-04-30 | Common Stock | 581 |  |  | D |  |
| Restricted Stock Unit | <sup>(2)</sup> |  |  |  |  |  |  | 2026-04-29<sup>(4)</sup> | 2028-04-29 | Common Stock | 2361 |  |  | D |  |
| Stock Option (Right to Buy) | $73.73 |  |  |  |  |  |  | 2022-05-04<sup>(5)</sup> | 2031-05-03 | Common Stock | 9465 |  |  | D |  |
| Stock Option (Right to Buy) | $87.10 |  |  |  |  |  |  | 2023-05-03<sup>(6)</sup> | 2032-05-02 | Common Stock | 9709 |  |  | D |  |
| Stock Option (Right to Buy) | $117.89 |  |  |  |  |  |  | 2024-05-02<sup>(7)</sup> | 2033-05-01 | Common Stock | 8990 |  |  | D |  |
| Stock Option (Right to Buy) | $129.22 |  |  |  |  |  |  | 2025-04-30<sup>(8)</sup> | 2034-04-29 | Common Stock | 8789 |  |  | D |  |
| Stock Option (Right to Buy) | $84.71 |  |  |  |  |  |  | 2026-04-29<sup>(9)</sup> | 2035-04-28 | Common Stock | 8060 |  |  | D |  |

---

### Footnotes:

(1) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025, and 5/2/2026.

(2) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

(3) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026, and, 4/30/2027.

(4) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027, and, 4/29/2028.

(5) The options became exercisable in equal installments in on 5/4/2022, 5/4/2023, and 5/4/2024.

(6) The options became exercisable in equal installments on 5/3/2023, 5/3/2024, and 5/3/2025.

(7) The options vest and become exercisable in equal installments on 5/2/2024, 5/2/2025, and 5/2/2026.

(8) The options vest and become exercisable in equal installments on 4/30/2025, 4/30/2026, and 4/30/2027.

(9) The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.

**Remarks:**
This amendment is being filed solely to: (a) update footnote 6 to correct the schedule on which the applicable options became exercisable and (b) attach a Power of Attorney that was inadvertently omitted from the original filing. Exhibit 24: Power of Attorney is attached.

**Signature:** /s/ Kelly E. W. Grez as Attorney-in-Fact for David R. Maraldo  
**Date:** 2026-05-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**